Pharma BD Deal Intelligence
Roundup litigation cost $20B+ settlements, $12.9B write-downs, 70% market cap destroyed
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Frankfurt School professor Michael Grote noted larger and more diversified firms are valued less than specialized firms, describing the deal as on the negative…
Bayer bids $66 billion for Monsanto in the largest acquisition of 2016 in any sector, offering a 44% premium to Monsantos share price before takeover talk was…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Bayer acquired Monsanto for $63 billion ($128 per share) in an all-cash transaction, creating a global leader in agriculture and life sciences. The deal faced extensive regulatory review and required significant divestitures.
Roundup litigation cost $20B+ settlements, $12.9B write-downs, 70% market cap destroyed
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Monsanto Company (this deal) | 2016 | $63.0B | 35 |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2016 deals · Bayer AG deals · Multiple (undisclosed) deals